Insulin resistance: targeting dyslipidemia beyond the LDL-cholesterol. Disclosures: Presentation outline
|
|
- Sherman Murphy
- 5 years ago
- Views:
Transcription
1 Insulin resistance: targeting dyslipidemia beyond the LDL-cholesterol Rocky Mountain Metabolic Syndrome Symposium May 14 th 21 Mori Krantz MD FACC Associate Professor, University of Colorado Director of CV Prevention Programs, CPC Staff Cardiologist, Denver Health Disclosures: Speaking and grant support: GSK, Pfizer Major stock holder: none Acknowledgment: selected slides from AHA Spotlight series lipid group Presentation outline Describe all components of the metabolic syndrome How common is this syndrome? Understand pathogenesis of insulin resistance & atherogenic dyslipidemia What is our principal focus to reduce CVD in DM? Lipids vs. Glycemic control Treatment of LDL cholesterol Beyond LDL cholesterol Are there better predictors of CVD risk than LDL-C? Review the concept of residual risk Atherogenic dyslipidemia defined: lipid particles made simple Does size matter? Are Triglycerides (TG) an independent CVD risk factor? Non-HDL-C, ApoB, and the TC/HDL ratio What are the therapeutic strategies for atherogenic dyslipidemia? Fibrates, Omega-3 fatty acids, Niacin, Diet, Exercise Treatment targets Q & A
2 Components of the metabolic syndrome (a precursor to diabetes) Risk Factor ( 3) Defining Level Central Abdominal obesity Waist circumference >4 & 35 inches (men/women) Triglycerides 15 mg/dl HDL-C <4 mg/dl men <5 mg/dl women Blood pressure 13/ 85 mm Hg Fasting glucose 11 mg/dl NCEP Expert Panel. JAMA 21;285: The evolution of insulin resistance and the metabolic syndrome 85/6 95/65 11/7 155/98 The Economist, December 11, 23 Obesity & diabetes track in US adults Diabetes 25% increase US adults (%) 5.3 Obesity (BMI 3 kg/m 2 ) 3% increase * * *Jan June CDC. 24 NHIS; Accessed August 25.
3 Incidence of CVD by the number of components of the Metabolic Syndrome Odds Ratio No. of Components Diabetes Care 25:179, 22 Over half of patients referred to cardiologists have insulin resistance Patients with insulin resistance syndrome (%) Cardiac rehabilitation Acute MI N = 1912 Savage, 25 N = 235 Milani, 23 N = 85 Curran, 24 Savage PD et al. Am Heart J. 25;149: Milani RV, Lavie CJ. Am J Cardiol. 23;92:5-4. Curran PJ et al. J Am Coll Cardiol. 24;43(suppl A):249A. Insulin Resistance Etiology: Central Adiposity (not inert but metabolically active) C-Reactive Protein ^ (inflammatory marker) FREE FATTY ACIDS Adiponectin (insulin sensitizer) Kershaw EE, et al. J Clin Endocrinol Metab. 24;89: Lee YH, et al. Curr Diab Rep. 25;5:7-75. Boden G, et al. Eur J Clin Invest. 22;32:
4 Atherogenic Dyslipidemia: the hallmark of metabolic syndrome Elevated Triglycerides (>15 mg/dl) Reduced HDL-C (<4 mg/dl in men; <5 mg/dl in women) Elevated small dense LDL particles Highly likely in the setting of elevated TG, reduced HDL-c and borderline elevated LDL-c Elevated non-hdl-c and/or Apo B 1 NHANES: Room for improvement < 5% of Diabetics Achieve Risk-Factor Goals Adults With Diabetes (%) NHANES III (N=124) NHANES (N=37) HbA 1c <7% BP <13/8 mmhg TC <2 mg/dl Good Control * *Good control indicates HbA 1c, BP, and TC were at recommended levels. National Health and Nutrition Examination Study (NHANES): cross-sectional survey of a nationally representative sample of the noninstitutionalized civilian US population, aged 2 years and older, with previously diagnosed diabetes. Saydah S et al. JAMA. 24;291: We ve gotten worse in terms of glycemic control and better with regard to lipids. Should I focus on lipids or blood sugar?
5 ACCORD: Study design N = 1,251 with T2DM and existing CVD or additional CV risk factors BP trial (n) Lipid trial* (n) SBP <12 mg Hg SBP <14 mg Hg Group A Group B Glycemia trial A1C <6% A1C 7.%-7.9% *Statin + fibrate vs statin, treatment group assignment blinded until end of trial Primary outcome: CV death, MI, stroke ACCORD Study Group. Am J Cardiol. 27;99(suppl):21i-33i. ACCORD: Treatment effects on glucose control Standard therapy A1C (%) Intensive therapy Time (years) ACCORD Study Group. N Engl J Med. 28;358: ACCORD: significant increase in death with intensive therapy Patients with events (%) HR 1.22 ( ) P = Time (years) CVD Death: HR 1.35 ( ) P=.2 Intensive therapy Standard therapy ACCORD Study Group. N Engl J Med. 28;358:
6 ADVANCE: Study design N = 11,14 with T2DM and high risk for CV events Perindopril + Indapamide Placebo Intensive glucose control Intensive glucose control + Perindopril/Indapamide Intensive glucose control + Placebo Standard glucose control Standard glucose control + Perindopril/Indapamide Standard glucose control + Placebo n = 5569 n = 5571 Primary outcome: Macro (CV death, MI, stroke), micro (new/worsening nephropathy, retinopathy) ADVANCE Collaborative Group. J Hypertens. 21;19(suppl 4):S21-S28. ADVANCE Treatment effect on glucose control Mean A1C (%) Standard control P <.1 6. Intensive control Follow-up (months) ADVANCE Collaborative Group. N Engl J Med. 28;358: ADVANCE: Effect on macrovascular outcomes CV death, MI stroke 25 Cumulative incidence (%) HR.94 ( ) P =.32 Standard control Intensive control Follow-up (months) ADVANCE Collaborative Group. N Engl J Med. 28;358:
7 NCEP: approach to lipids Step one - No surprise - lower LDL-C HPS and CARDS: Benefits of lowering LDL-C in diabetes HPS All diabetes Event rate (%) Statin Placebo Statin better.73 Placebo better P <.1 _ LDL-C (mg/dl)* 34.8 Diabetes, no CVD CARDS Relative risk 1.7 *Statin vs placebo HPS = Heart Protection Study CARDS = Collaborative Atorvastatin Diabetes Study HPS Collaborative Group. Lancet. 23;361: Colhoun HM et al. Lancet. 24;364: ASCOT-LLA: Statin reduces CV events in DM & HTN N = 2532, baseline LDL-C 128 mg/dl 14. % % Risk reduction P = HR =.77 (.61.98) Years Number at risk Placebo Atorvastatin Nonfatal MI, CV mortality, UA, stable angina, arrhythmias, stroke, TIA, PAD, retinal vascular thrombosis, revascularization ASCOT-LLA = Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm Placebo Atorvastatin 1 mg Sever PS et al. Diabetes Care. 25;28:
8 NCEP approach: Step 2, beyond LDL The concept of residual dyslipidemia risk Residual Risk in Patients Treated With Intensive Statin Therapy N LDL-C (mg/dl)* Cannon CP, et al. N Engl J Med. 24;35: Pedersen TR, et al. JAMA. 25;294: LaRosa JC, et al. N Engl J Med. 25;352: Superko HR. Br J Cardiol. 26;13: *Mean or median LDL-C after treatment 23 Heart Protection Study Among Simvastatin-treated patients who entered the trial with LDL-C levels < 116 mg/dl and who had mean LDL-C levels of ~ 7 mg/dl during the study: The 5-year risk of a major vascular event was still 18%. This would equate to a 1-year risk of 35%. Heart Protection Study Collaborative Group. Lancet. 22;36:
9 Shortcomings of LDL: both calculated and measured Friedewald equation (LDL-C = TC HDL-C - TG/5) Cholesterol content in LDL varies between individuals Influenced by metabolic factors (insulin resistance) Changes with statin treatment Less accurate at LDL < 1 mg/dl Less accurate as triglycerides >15 mg/dl Does not represent all atherogenic ApoB-lipoproteins Does not accurately represent the number of LDL particles Direct LDL cholesterol measures Poor standardization Does not represent all atherogenic ApoB-containing lipoproteins 25 Atherogenic lipoproteins: non-hdl-c Non-HDL-C Apo B-containing lipoproteins VLDL IDL LDL Very low-density lipoprotein (VLDL) Made in the liver 1 TG-rich 1 Atherogenic 2 Intermediate-density lipoprotein (IDL) Formed from VLDL by TG lipolysis 1 Also known as a VLDL remnant particle 1 Atherogenic 2 Low-density lipoprotein (LDL) JUST ONE COMPONENT OF RISK Formed from IDL due to further TG lipolysis 1 Taken up by the liver and other organs via the LDL receptor 1 Major atherogenic particle 2 HDL High-density lipoprotein (HDL) Anti-atherogenic: carries cholesterol away from artery wall for metabolism or excretion 1 Other possible antiatherogenic effects include anti-inflammatory and antioxidant actions, and improvement in endothelial function 1 *Formed in the liver and cleared by LDL receptor. Apo=apolipoprotein; sdldl=small, dense low-density lipoprotein; TG=triglyceride. 1. Stone NJ, Blum CB. Management of Lipids in Clinical Practice. 25:24-27, 33, 34, Garg R et al. Prev Cardiol. 25;8: Are there stronger CVD risk predictors beyond LDL-C?
10 LDL-C a weaker predictor of CVD vs. non-hdl or ApoB Combined Analysis of >18, patients in TNT & IDEAL trials Measure Hazard Ratio Model 1* Hazard Ratio Model 1 + LDL-C Hazard Ratio Model 1 + Non-HDL Hazard Ratio Model 1 + Apo B LDL-C 1.15 ( ) P = <.1.9 ( ) P =.4.95 ( ) P =.33 Non-HDL-C 1.19 ( ) P = < ( ) P = < (1.-1.3) P =.6 ApoB 1.19 ( ) P = < ( ) P = < ( ) P =.47 * Model 1: age, sex and study (TNT / IDEAL) ÅòIncreasing LDL inversely associated with CVD events Kastelein JJ et al. Circulation. 28;117: Do I need to measure ApoB/Apo A ratio or is TC/HDL adequate? Answer: Minimal incremental predictive value in measuring Apolipoproteins ApoB better statistical agreement vs. TG and decreased variability Large economic cost What is perhaps the most common metabolic manifestations of obesity?
11 Hypertriglyceridemia Prevalence TG >5mg/dL 2_%-3% 5-6 MM Patients US Adult Population Total = 217 million Clinical Relevance Risk for pancreatitis Risk for CVD TG 2-499mg/dL ~13% MM Patients *This census is outdated as there are roughly 35 million in the US *Numbers exceeding metabolic syndrome cut-point (>15 mg/dl) are much greater Estimated from NCEP ATPIII guidelines data; US Census 23 Does high TG matter or just LDL-C? Incidence of CHD Events According to Serum LDL-C and TG Concentration* CHD Cases / 1 in 8 Years Baseline TG < 2 mg/dl Baseline TG 2 mg/dl < Baseline LDL-C (mg/dl) * Lipids from 4849 middle-aged men who were followed up for 8 years to record incidence of CHD. Study demonstrated that fasting levels of TGs were an independent risk factor for CHD events, irrespective of serum levels of LDL-C. CHD=coronary heart disease; LDL-C=low-density lipoprotein cholesterol; TG=triglyceride. Assmann G et al. Eur Heart J. 1998;19(suppl M):M8-M14. Hypertriglyceridemia Increases CHD Risk In Patients with good versus bad Ratios * * Bar represents 5% of subjects in which 25% of CHD events occurred Assmann G, Schulte H. Am J Cardiol. 1992;7: Copyright 1992, with permission from Excerpta Medica Inc. 33
12 Do high triglycerides matter? Independent predictor in post-acs patients Miller et al J. Am. Coll. Cardiol. 28;51; Triglycerides summary Independent Risk Factor for CHD Meta-analysis of 17 prospective studies that evaluated fasting TG levels and CVD endpoints 8 studies adjusted for HDL-C Results when adjusting for HDL-C Relative risk (RR) = 1.14 for men, RR = 1.37 for women Higher CVD risk for women Conclusion: elevated TG is a risk factor for CVD independent of HDL-C and the risk is greater for women Note: Triglyceride goals (< 15 mg/dl) are rarely achieved Hokanson JE, Austin MA. J Cardiovasc Risk. 1996;3: Impact of LDL Size Differences At the Same LDL Cholesterol Concentration Up to 7% More Particles 1 mg/dl Large LDL 1 mg/dl Small LDL Cholesterol Balance 36
13 High TG lead to a decrease in Particle Size & an increase in Particle Number Apo B Fewer Particles More Particles LDL= 13 mg/dl More Apo B Cholesterol Ester Correlates with: TC 198 mg/dl LDL-C 13 mg/dl TG 9 mg/dl HDL-C 5 mg/dl Non-HDL-C148 mg/dl Apo=apolipoprotein; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; TG=triglyceride. Otvos JD et al. Am J Cardiol. 22;9:22i-29i. Correlates with: TC 21 mg/dl LDL-C 13 mg/dl TG 25 mg/dl HDL-C 3 mg/dl Non-HDL-C18 mg/dl High Triglycerides Are Associated With LDL Subclass Pattern B = BAD Cumulative Percent Pattern A (large, fluffy) Pattern B (small, dense) TGs (mg/dl) LDL=low-density lipoprotein; TG=triglyceride. Austin MA, King MC, Vranizan KM, Krauss RM. Circulation. 199;82: Small, Dense LDL susceptibility to oxidation vascular permeability Conformational change in ApoB component affinity for LDL receptor for hepatic clearance Association with insulin resistance = high TG and low HDL-C (atherogenic dyslipidemia phenotype) Austin MA et al. Curr Opin Lipidol. 1996;7:
14 Outcomes: Technically, Size doesn t matter particle number does The relationship between small LDL particle size and CHD is intertwined with a complex physiologic syndrome atherogenic dyslipidemia which includes high TG, low HDL-C, and increased LDL particle number Following multivariate analysis that includes TGs, HDL- C, and LDL-particle number among 17 cross-sectional, 8 prospective and 6 interventional trials: LDL particle size is rarely a significant, independent predictor of CHD events Cromwell WC, Otvos JD. Curr Atheroscler Rep. 24;6: Women s Health Study CVD Relative Risk* and Lipid Quartiles P<.1 P<.5 P<.1 P=.8 P=.2 Quartile of Lipid *Adjusted for aspirin or vitamin E use Blake GJ et al. Circulation. 22;16: Cholesterol (mg/dl) Why use Non-HDL-C Goals? Treatment approach case 1 vs. case Case 1 Case 2 VLDL LDL HDL VLDL TC= 29 mg/dl TG 12 mg/dl 4 mg/dl VLDL-C 24 mg/dl 88 mg/dl LDL-C 145 mg/dl 89 mg/dl (may not trigger Rx) HDL-C 4 mg/dl 32 mg/dl Non-HDL-C 169 mg/dl 177 mg/dl (should Non-HDL-C trigger goal = LDL-C Rx) goal + 3 TG/HDL-C ratio TC/HDL-C ratio TC 29 mg/dl 29 mg/dl LDL HDL HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; TG=triglyceride; VLDL=very low-density lipoprotein. Non-HDL Cholesterol = 177 mg/dl
15 Because Non-HDL contains Apo-B, all of these particles are involved in Atherogenesis All ApoB lipoproteins: LDL, IDL, VLDL, RLP 21 Modified from Crawford MH, DiMarco JP, editors: Cardiology, London, 21, Mosby. Mosby items and derived items copyright 24, 2 by Mosby, Inc. 43 An Unmet Clinical Need for TG Reduction in Insulin resistant patients: Rx options Niacin Omega 3 s Fibrates Statins Fibrates Primary and Secondary Prevention: limited older data: more recent trials no benefit in FIELD and ACCORD 42% 22% 9% *** 34% 66% *** Primary Prevention Secondary Prevention Frick MH et al. N Engl J Med. 1987;317: Manninen V et al. Circulation. 1992;85:37-45 The BIP Study Group. Circulation. 2;12:21-27 Rubins HB et al. N Engl J Med. 1999;341: *Post hoc analysis of subgroup with TG > 2 mg/dl and HDL-C < 42 mg/dl **Post hoc analysis of subgroup with TG 2 mg/dl and HDL-C < 35 mg/dl ***Difference between placebo and Rx for primary endpoint was statistically significant (P <.5) 45
16 Niacin vs. Placebo among Insulin Resistance Patients: older data 6-yr AMI rate by baseline FPG Hazard Ratio Placebo Niacin 15 Event Rate, % 1 5 < FBG, mg/dl n=1119 for niacin; n=2787 for placebo. * z for interaction =.44 (p=.66); indicates homogeneity. CORONARY DRUG PROJECT (CDP) Canner PL et al. Am J Cardiol. 25;95: Addition of Omega-3 FA esters 4 g/day in Patients Taking Simvastatin with Triglycerides mg/dl Parameter Non-HDL-C TG TC VLDL-C Apo B HDL-C LDL-C Simvastatin + Omega-3 (n=122) Simvastatin + Placebo (n=132) BL EOT Median BL EOT % Chg* Median % Chg* < Difference P value <.1 <.5 <.5 <.5 <.5 =.5 *Response to the addition of Omega-3 fatty acids, 4 g/day after 8 weeks of simvastatin 4 mg therapy during lead-in Davidson et al. Apo=apolipoprotein; BL=baseline; EOT=end of treatment; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; TG=triglyceride; VLDL-C=very low-density lipoprotein cholesterol. Suggested Treatment Goals In Dyslipidemia Patients at High Risk LDL-C goal (mg/dl) Non-HDL-C goal (mg/dl ApoB goal (mg/dl) Highest-risk patients: Known CVD; or <7 <1 <8 (or 7 per Dr. Eckel) Diabetes + > 1 major CVD risk factor* High-risk patients: No diabetes/known CVD AND >2 major CVD risk factors*; or <1 <13 <9 Diabetes without major CVD risk factors* Adapted from Lipoprotein Management in Patients with Cardiometabolic Risk (Diabetes Care 28; 31: CVD = cardiovascular disease. * Major CVD risk factors = smoking, HTN, family history of premature coronary artery disease 48
17 49 Don t forget Lifestyle Lyon Heart Study % P= % P= % P<.1-61% 8 P<.5 7 Numbers in bars are # of events De Lorgeril M, et al. Arch Intern Med. 1998;158:1161. Circulation. 1999;99:779. Guess my syndrome (X)? Conclusions Insulin resistance (metabolic syndrome) is a growing epidemic BP & lipid control more important than glycemic control or aspirin to lower CVD risk in this primary prevention population Atherogenic dyslipidemia mediates the increased risk for CVD The strongest predictors of CVD include: TC/HDL ratio (or ApoB/Apo A ratio) Non-HDL cholesterol (VLDL, LDL, IDL) LDL is actually a weaker CVD risk predictor Nonetheless, achieving LDL goals is the first step and we have the best prospective data for this paradigm Next, manage high TG and low HDL Exercise Dietary modification Omega-3s, Niacin, Fibrates Though further outcome studies are warranted
Cardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationElevated Triglycerides Increase the Risk of CHD at All Levels of LDL-C Incidence of CHD Events According to Serum LDL-C and TG Concentration*
Overview of LOVAZA Importance of Treating Very High Triglycerides (!5 mg/dl) in Adult Patients Pathophysiology and Clinical Importance of Very High Classification and Treatment Approaches for Very High
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationN-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP
Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationPopulation versus Personalized Medicine in the Clinical Management of CV Disease
Population versus Personalized Medicine in the Clinical Management of CV Disease Discussion Regarding Individualized Approaches to the Management of CV Risk Robert M. Honigberg, MD Key Questions Do management
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More information